The FDA has cleared an expanded indication of a combination of NuVasive’s Modulus Cervical interbody implant with Attrax Putty bone void filler.

Attrax Putty is the first synthetic bone graft substitute to receive FDA clearance for use in thoracolumbar interbody fusion spacers.

The devices are part of the company’s C360 portfolio, which focuses on the anterior and posterior cervical spine.

The combination of the Modulus implant and Attrax Putty were validated in clinical studies as “having clinical and economic advantages over traditional, non-porous interbody implants and premium-priced biologics,” the company said.